HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. VRC01-class bnAbs that target the CD4 binding site (CD4bs) of trimeric HIV-1 envelope (Env) glycoprotein spikes are particularly attractive to elicit because of their extraordinary breadth and potency...

Full description

Bibliographic Details
Main Authors:	Celia C LaBranche, Andrew T McGuire, Matthew D Gray, Shay Behrens, Peter D Kwong, Xuejun Chen, Tongqing Zhou, Quentin J Sattentau, James Peacock, Amanda Eaton, Kelli Greene, Hongmei Gao, Haili Tang, Lautaro G Perez, Kevin O Saunders, John R Mascola, Barton F Haynes, Leonidas Stamatatos, David C Montefiori
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-11-01
Series:	PLoS Pathogens
Online Access:	http://europepmc.org/articles/PMC6237427?pdf=render

Similar Items

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
by: K. Rachael Parks, et al.
Published: (2019-12-01)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-09-01)

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-12-01)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
by: Maria L. Knudsen, et al.
Published: (2022-11-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01)

Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors
by: Christina Yacoob, et al.
Published: (2016-11-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
by: Han D, et al.
Published: (2012-09-01)

Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.
by: Anton N Chikaev, et al.
Published: (2015-01-01)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
by: LaBranche, C, et al.
Published: (2019)

Partial germline reversions can increase VRC07 potency and breadth
by: Rudicell RS, et al.
Published: (2012-09-01)

Emission trading with profit-neutral permit allocations
by: Quah, J, et al.
Published: (2012)

Emissions Trading with Profit-Neutral Permit Allocations.
by: Hepburn, C, et al.
Published: (2008)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
by: Chakrabarti BK, et al.
Published: (2012-09-01)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
by: Yuka Otsuka, et al.
Published: (2018-08-01)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
by: Guo D, et al.
Published: (2012-09-01)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
by: Capucci, S, et al.
Published: (2017)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
by: E. Fabian Cardozo-Ojeda, et al.
Published: (2021-08-01)

First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody
by: Denis R. Beckford-Vera, et al.
Published: (2022-03-01)

Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.
by: Hugh C Welles, et al.
Published: (2022-06-01)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
by: Jeong Hyun Lee, et al.
Published: (2021-09-01)

Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques.
by: Yvonne J Rosenberg, et al.
Published: (2016-01-01)

Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques
by: Bowles, EJ, et al.
Published: (2014)

Neutralization of HIV-1 by antibody.
by: Sattentau, Q
Published: (1996)

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
by: Ema T Crooks, et al.
Published: (2015-05-01)

Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice
by: Xuejun Chen, et al.
Published: (2022-03-01)

Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
by: Christopher A. Cottrell, et al.
Published: (2021-11-01)

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
by: Martina S. Wesley, et al.
Published: (2021-08-01)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021-01-01)

Mechanisms of virus neutralization by antibody.
by: Klasse, P, et al.
Published: (2001)

FINAD + VRC = Controllers Instituut
by: G. H. Koolman
Published: (1995-05-01)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
by: Andrew J Borst, et al.
Published: (2018-11-01)

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
by: Nathanael P McCurley, et al.
Published: (2017-01-01)

High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers
by: Iván del Moral-Sánchez, et al.
Published: (2022-02-01)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.
by: Silvia Capucci, et al.
Published: (2017-01-01)